Summary
is the purpose of the study. To evaluate the effectiveness of consistent therapy with Mexidol and Mexidol Fort 250 compared to placebo in patients with chronic brain ischemia (chemical) of different age -related subgroups. Material and methods. Subanalis of data of an international multicenter randomized double-centered placebo-controlled study of Memo, in which 318 patients (25% of men) aged 40 to 90 (median 60) years participated. The effectiveness of treatment was estimated in three age groups: 40-60 (n = 163), 61–75 (n = 141) and 76–90 (n = 13) years. As the primary final point of efficiency, the axis considered the increase in the dynamics of the amount of points on the MOCA scale in the form of an absolute difference between the amount of points before the start of treatment and on the 75th day of therapy. As a secondary endpoint of efficiency, the speaker was considered by the amount of points on the following questionnaires and scales: a test of digital symbol replacements, a questionnaire for the quality of life of the SF-36, a scale of subjective assessment of asthenia MFI-20, a Vein vegetative impaired questionnaire, a Bek anxiety scale, a thinetti motor activity scale.
Results.
The positive dynamics of the severity of cognitive, emotional and motor disorders in groups 40-60 and 61–75 years after 75 days of therapy was detected in patients who received both Mexidol and placebo, however, in patients receiving Mexidol, these changes turned out to be more pronounced, which indicate the higher values of the absolute difference in the amount of the points of the studied indicators.
Conclusion.
The results of the study have shown that in patients with Khim, a significant improvement in cognitive and motor functions, improving the quality of life, a decrease in the severity of autonomic disorders, asthenia
and anxiety after 75 days of therapy were observed against the background of the use of Mexido compared to placebo. The
results indicate the appropriateness of the use of Mexidol for the treatment of patients of different ages with chemicals.
Key words:
Cognitive disorders, chronic brain ischemia, Mexidol, Mexidol Fort 250, ethylmethylhydroxypyridine succinate, examination of memes.